224 related articles for article (PubMed ID: 34139345)
1. New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
He Y; Luo Y; Huang L; Zhang D; Wang X; Ji J; Liang S
Pharmacol Res; 2021 Aug; 170():105732. PubMed ID: 34139345
[TBL] [Abstract][Full Text] [Related]
2. Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2024 May; 203():107181. PubMed ID: 38614375
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
4. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
Roulin D; Waselle L; Dormond-Meuwly A; Dufour M; Demartines N; Dormond O
Mol Cancer; 2011 Jul; 10():90. PubMed ID: 21791089
[TBL] [Abstract][Full Text] [Related]
5. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib for the treatment of renal cancer.
Strumberg D
Expert Opin Pharmacother; 2012 Feb; 13(3):407-19. PubMed ID: 22263843
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib treatment promotes metastasis of drug-resistant renal cell carcinoma via TFE3 signaling pathway.
Li L; Zhao S; Liu Z; Zhang N; Pang S; Liu J; Liu C; Fan Y
Cell Death Dis; 2021 Feb; 12(2):220. PubMed ID: 33637706
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma.
Xu Z; Yang F; Wei D; Liu B; Chen C; Bao Y; Wu Z; Wu D; Tan H; Li J; Wang J; Liu J; Sun S; Qu L; Wang L
Oncogene; 2017 Apr; 36(14):1965-1977. PubMed ID: 27841868
[TBL] [Abstract][Full Text] [Related]
9. Sequencing systemic therapies in advanced RCC: is there a best strategy?
Powles T; Crusz SM
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714492
[TBL] [Abstract][Full Text] [Related]
10. Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.
Liu S; Gao M; Wang X; Ding S; Lv J; Gao D; Wang Z; Niu Z
Oncotarget; 2016 Nov; 7(48):79141-79153. PubMed ID: 27816967
[TBL] [Abstract][Full Text] [Related]
11. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation.
Marona P; Górka J; Kwapisz O; Jura J; Rys J; Hoffman RM; Miekus K
Cell Death Dis; 2022 Sep; 13(9):814. PubMed ID: 36138026
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract][Full Text] [Related]
13. Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma.
Zhang L; Xie D; Lei Y; Na A; Zhu L
Future Oncol; 2021 Aug; 17(23):3051-3060. PubMed ID: 33906367
[No Abstract] [Full Text] [Related]
14. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
[TBL] [Abstract][Full Text] [Related]
15. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
Zheng B; Zhu H; Gu D; Pan X; Qian L; Xue B; Yang D; Zhou J; Shan Y
Biochem Biophys Res Commun; 2015 Apr; 459(2):234-239. PubMed ID: 25712526
[TBL] [Abstract][Full Text] [Related]
16. PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma.
Sekino Y; Hagura T; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shigeta M; Taniyama D; Kuraoka K; Sentani K; Yasui W; Matsubara A
Anticancer Res; 2020 Apr; 40(4):1943-1951. PubMed ID: 32234883
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
18. Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC.
Wright KM
Oncology (Williston Park); 2020 Jul; 34(7):257. PubMed ID: 32674211
[TBL] [Abstract][Full Text] [Related]
19. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
Rosa R; Damiano V; Nappi L; Formisano L; Massari F; Scarpa A; Martignoni G; Bianco R; Tortora G
Br J Cancer; 2013 Aug; 109(3):686-93. PubMed ID: 23839492
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA GAS5 sensitizes renal cell carcinoma to sorafenib via miR-21/SOX5 pathway.
Liu L; Pang X; Shang W; Xie H; Feng Y; Feng G
Cell Cycle; 2019 Feb; 18(3):257-263. PubMed ID: 29895198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
